Latest Headlines

Latest Headlines

With a sweetened $2.9B bid, Bayer nabs its Xofigo partner, Algeta

Bayer considers itself a disciplined M&A strategist. Apparently, its discipline stretched far enough to accommodate a $500 million increase in its bid for Algeta, the Norwegian drugmaker that's also its partner on the Xofigo cancer treatment.

Bayer bags Algeta's cancer drug portfolio for $2.9B

It took a half-billion-dollar sweetener, but Bayer has closed the deal to buy its cancer drug partner Algeta for $2.9 billion in cash. The buyout leaves Bayer with full control of the prostate cancer drug Xofigo along with a pipeline that includes a potential next-gen successor to the targeted radioactive therapy.

Bayer bids $2.4B for Xofigo partner Algeta in drive for cancer growth

When Bayer CEO Marijn Dekkers stepped into the job in 2010, he had a trove of cash, and he promised to spend a big chunk on deals. A $23 billion chunk, in fact. Since then, the German conglomerate hasn't exactly been audacious in the M&A arena. Bayer has snapped up a healthcare company or three, but it's quick to back away if a price gets too rich.

UPDATED: Bayer's $2.4B bid to buy Algeta fits neatly with cancer drug strategy

Earlier this year, Bayer happily heralded the FDA's approval of Xofigo for castration-resistant prostate cancer as an important milestone for its steadily growing portfolio of cancer therapies. And now the German pharma company has set its sights on bagging Algeta--the Norwegian company that discovered the therapy and subsequently partnered with Bayer--for $2.4 billion.

Glaxo, Roche, J&J and others score backing on big day for EU regulator

Friday, the EU's Committee for Medicinal Products for Human Use (CHMP) recommended 11 new drugs for a variety of diseases--the most nods it's given in a single meeting all year.

UPDATED: FDA OKs pinpoint prostate cancer radiation drug Xofigo from Bayer, Algeta

The approval comes just three months after the FDA granted priority review status for Alpharadin, a radiopharmaceutical from Bayer and Norway's Algeta that will now enter an increasingly competitive--and growing--market.

Bayer, Algeta nab priority review for prostate cancer drug

In-licensed from Norway's Algeta, Alpharadin is one of the pharma company's top late-stage prospects, following a string of regulatory wins on the development front.

Medivation surges as rivals aim at fast-changing prostate cancer market

Shares of Medivation ($MDVN) jumped 17% today after the drug developer confirmed some promising Phase III data on the closely-watched prostate cancer therapy MDV3100 and added some reassuring numbers

Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field

The experimental prostate cancer drug Alpharadin took center stage at the big EMCC meeting in Stockholm, with researchers reporting that they had suspended a registration trial after

Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful

Bayer and its biotech partner Algeta took a big step today toward a relatively quick FDA decision on their closely-watched prostate cancer drug Alpharadin (radium-223 chloride). Regulators are